FierceBiotech Jan 19, 2026 AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta
FierceBiotech Jan 19, 2026 Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions
FierceBiotech Jan 16, 2026 Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program
FierceBiotech Jan 16, 2026 ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial
FierceBiotech Jan 16, 2026 JPM26: Chugai chases new science and name recognition from US biopharma industry
FierceBiotech Jan 15, 2026 Boston Scientific to snap up thrombectomy specialist Penumbra in deal valued at $14.5B
FierceBiotech Jan 15, 2026 Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas
FierceBiotech Jan 15, 2026 Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs
FierceBiotech Jan 15, 2026 Italy's Alfasigma pens €125M deal for injectable form of German biotech's HSV treatment
FierceBiotech Jan 15, 2026 JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns
FierceBiotech Jan 14, 2026 JPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases
FierceBiotech Jan 14, 2026 JPM26: Illumina working with China on 'a path through' its export troubles, sees academic research environment 'muted' for '26